At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 111 enrolled
Drug / intervention
Ketorolac +1 moredrug
Likely dose
Ketorolac 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy of Continuous Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy: a Double Blinded Randomized Placebo Controlled Trial.
In Brief
A Phase 4 clinical trial evaluating Ketorolac and Placebo for Nephrectomy and Laparoscopic Donor Nephrectomy. Completed, enrolled 111 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether continuous intravenous ketorolac infusion reduces pain in patients who are having laparoscopic surgery to donate a kidney.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNephrectomy, Laparoscopic Donor Nephrectomy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionNov 2010
TodayJul 2026
First PostedOct 2, 2008
Enrollment StartOct 1, 2008
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.8 years ago
Interventions
Ketorolacdrug
90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Placebodrug
1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.